Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Follicular Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Lymphoma
Interventions: Rituximab, Lenalidomide, Valemetostat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 19
States / cities: Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more

Conditions: Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Thrombocytopenia
Interventions: Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lymphoma, B-Cell
Interventions: CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota

Conditions: Recurrent Follicular Lymphoma
Interventions: idelalisib, lenalidomide; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • St Louis, Missouri + 3 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Reem Karmali; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Tafasitamab, Venetoclax; Procedure · Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Myeloma
Interventions: Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome
Interventions: lenalidomide, cyclosporine A; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloma Multiple
Interventions: Belantamab mafodotin, Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Blinatumomab, Lenalidomide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Ibrutinib, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Myelodysplastic Syndrome
Interventions: Ezatiostat Hydrochloride, Lenalidomide (Revlimid®); Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ofatumumab, Lenalidomide; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Charleston, South Carolina • Greenville, South Carolina

Conditions: B-cell Chronic Lymphocytic Leukemia
Interventions: B-CLL Vaccine, Lenalidomide; Biological · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Lenalidomide Induction, Sequential Maintenance Therapy; Drug
Lead sponsor: Cristina Gasparetto; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: Elranatamab, Lenalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 24
States / cities: Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Recurrent/Refractory CNS, Intraocular Lymphoma
Interventions: Lenalidomide, Rituximab; Drug
Lead sponsor: James Rubenstein; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions: Anakinra, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Placebo; Biological · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Lenalidomide Pill, Dexamethasone, Daratumumab; Drug
Lead sponsor: Attaya Suvannasankha; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: dexamethasone, pomalidomide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis